|
20 Nov 2009 |
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Company's TAP Technology
|
|
19 Nov 2009 |
Merck KGaA: CHMP Opinion for Erbitux in Advanced Non-Small Cell Lung Cancer
|
|
18 Nov 2009 |
Innate Pharma initiates collaboration with Celgene to evaluate the clinical potential of REVLIMID® combined with anti-kir antibody IPH 2101 in patients with multiple myeloma
|
|
18 Nov 2009 |
Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia
|
|
17 Nov 2009 |
Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate SGN-75
|
|
17 Nov 2009 |
Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with Advanced Breast Cancer
|
|
17 Nov 2009 |
HUMAN GENOME SCIENCES RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR RAXIBACUMAB BIOLOGICS LICENSE APPLICATION
|
|
17 Nov 2009 |
ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma
|
|
16 Nov 2009 |
Human Genome Sciences Receives Complete Response Letter from FDA for Raxibacumab Biologics License Application
|
|
16 Nov 2009 |
BioInvent and ThromboGenics Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients with Advanced Solid Tumours
|
|
13 Nov 2009 |
BioInvent signs licensing agreement with Daiichi Sankyo for the discovery and development of therapeutic antibodies
|
|
12 Nov 2009 |
Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
|
|
11 Nov 2009 |
Sanofi-aventis and Regeneron expand strategic Antibody Collaboration
|
|
09 Nov 2009 |
MorphoSys Receives Regulatory Approval to Start Phase 1b/2a Clinical Trial for MOR103 Program
|
|
09 Nov 2009 |
GENMAB ANNOUNCES START OF OFATUMUMAB PHASE III HEAD TO HEAD STUDY IN DLBCL
|
|
09 Nov 2009 |
Anti-Malignancy Agent Avastin® Obtained Approval for Additional Indication of Non-Small Cell Lung Cancer
|
|
05 Nov 2009 |
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
|
|
04 Nov 2009 |
Phase 2 Trial of XOMA 052 to be Initiated in Type 1 Diabetes Patients
|
|
03 Nov 2009 |
XOMA Signs Antibody Discovery Collaboration With Kaketsuken
|
|
03 Nov 2009 |
FibroGen Announces New Research in Anti-CTGF and HIF-PHI
|
|
03 Nov 2009 |
Calmune and Crucell Enter Exclusive Research Collaboration
|
|
02 Nov 2009 |
GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus
|
|
02 Nov 2009 |
INNATE PHARMA MOVES FORWARD ANTI-KIR MONOCLONAL ANTIBODY IPH 2101 DEVELOPMENT WITH STUDY EXTENSION IN ACUTE MYELOID LEUKEMIA
|
|
29 Oct 2009 |
Micromet and Sanofi-aventis Sign Global Collaboration and License Agreement for New Solid Tumor BiTE Antibody
|
|
29 Oct 2009 |
Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
|
